Experiense of treatment with a growth hormone receptor antagonist in patients with hereditary form of acromegaly: clinical cases

Acromegaly is a severe neuroendocrine disease caused by chronic excessive production of somatotropic hormone (STH), characterized by specific changes in appearance, metabolic disorders. In 95% of cases, the cause of pathology is STH-producing pituitary adenomas. The priority method of treatment for acromegaly is transnasal transsphenoidal adenomectomy. If it is impossible to carry out neurosurgical intervention, in order to prevent the progression of the disease and the development of complications, patients are recommended drug therapy with long-acting somatostatin analogues, and if their effectiveness is low, additional radiation therapy may be applied to the neoplasm area. The usage of a relatively new group of drugs, antagonists of STH receptors, namely Pegvisomant for the purpose of drug treatment of acromegaly demonstrates high efficacy even in cases of aggressive forms resistant to other types of treatment. In this article we present two clinical cases of hereditary acromegaly, when the initiation of Pegvisomant therapy led to the achievement of clinical and laboratory remission of acromegaly in patients with an aggressive form of the disease, accompanied by continued growth of residual neoplasm tissue and preservation of its secreting ability even after surgical interventions, radiatiotherapy and long-term drug treatment with somatostatin analogues. The results of the above clinical cases confirm the success of mono- or combined (in cases with continued growth of the neoplasm) therapy with a growth hormone receptor antagonist, Pegvisomant, especially in the case of aggressive acromegaly.

1. Cuevas-Ramos D, Fleseriu M. Somatostatin receptor ligands and resistance to treatment in pituitary adenomas. J Mol Endocrinol. 2014;52(3):R223-R240. doi: https://doi.org/10.1530/JME-14-0011

2. Laws ER, Ezzat S, Asa SL, et al. Pituitary Disorders: Diagnosis and Management. Wiley-Blackwell. 2013.

3. Chahal HS, Chapple JP, Frohman LA, et al. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA). Trends Endocrinol Metab. 2010;21(7):419-427. doi: https://doi.org/10.1016/j.tem.2010.02.007

4. Naves LA, Daly AF, Vanbellinghen J-F, et al. Variable pathological and clinical features of a large Brazilian family harboring a mutation in the aryl hydrocarbon receptorinteracting protein gene. Eur J Endocrinol. 2007;157(4):383-391. doi: https://doi.org/10.1530/EJE-07-0533

5. Obshchestvennaia organizatsiia «Rossiiskaia assotsiatsiia endokrinologov». Akromegaliia: klinika, diagnostika, differentsial’naia diagnostika, metody lecheniia. Klinicheskie rekomendatsii. Moscow: 2014. (In Russ.).

6. Tuominen I, Heliövaara E, Raitila A, et al. AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling. Oncogene. 2015;34(9):1174-1184. doi: https://doi.org/10.1038/onc.2014.50

7. Vasilev V, Daly AF, Petrossians P, Zacharieva S, Beckers A. Familial Pituitary Tumor Syndromes. Endocr Pract. 2011;17(9):41-46. doi: https://doi.org/10.4158/EP11064.RA

8. Available from: https://ec.bioscientifica.com/view/journals/ec/8/4/ EC-19-0004.xml [cited 16.08.22].

9. Stiles CE, Korbonits M. Familial Isolated Pituitary Adenoma. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000. 2020 May 28.

10. Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary. 2017;20(1):109-115. doi: https://doi.org/10.1007/s11102-016-0768-4

11. Buchfelder M, van der Lely A-J, Biller BMK, et al. Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY. Eur J Endocrinol. 2018;179(6):419-427. doi: https://doi.org/10.1530/EJE-18-0616

12. Feola T, Cozzolino A, Simonelli I, et al. Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies. J Clin Endocrinol Metab. 2019;104(7):2892- 2902. doi: https://doi.org/10.1210/jc.2018-02281

13. Mazziotti G, Floriani I, Bonadonna S, et al. Effects of Somatostatin Analogs on Glucose Homeostasis: A Metaanalysis of Acromegaly Studies. J Clin Endocrinol Metab. 2009;94(5):1500-1508. doi: https://doi.org/10.1210/jc.2008-2332

14. Salenave S, Boyce AM, Collins MT, Chanson P. Acromegaly and McCune-Albright Syndrome. J Clin Endocrinol Metab. 2014;99(6):1955-1969. doi: https://doi.org/10.1210/jc.2013-3826

15. Zhai X, Duan L, Yao Y, et al. Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review. Front Endocrinol (Lausanne). 2021;12(6):1955-1969. doi: https://doi.org/10.3389/fendo.2021.672394

16. Galland F, Kamenicky P, Affres H, et al. McCune-Albright Syndrome and Acromegaly: Effects of Hypothalamopituitary Radiotherapy and/or Pegvisomant in Somatostatin AnalogResistant Patients. J Clin Endocrinol Metab. 2006;91(12):4957-4961. doi: https://doi.org/10.1210/jc.2006-0561

17. Akintoye SO, Kelly MH, Brillante B, et al. Pegvisomant for the Treatment of gsp-Mediated Growth Hormone Excess in Patients with McCune-Albright Syndrome. J Clin Endocrinol Metab. 2006;91(8):2960-2966. doi: https://doi.org/10.1210/jc.2005-2661

18. Fleseriu M, Führer-Sakel D, van der Lely AJ, et al. More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol. 2021;185(4):525-538. doi: https://doi.org/10.1530/EJE-21-0239